Behind every great health innovation is expert guidance. At Kilo, our Medical Advisory Board brings together leading healthcare professionals who help shape our products through the lens of clinical experience, scientific evidence, and real-world patient care. We’re excited to introduce the experts behind the Board and share their perspectives on the future of health, prevention, and advanced medicine.
To kick off our profile series, we sat down with our first guest, Dr. Robertas Pranevičius, an interventional cardiologist with international clinical experience across Lithuania, Norway, and Austria. Dr. Pranevičius treats patients with coronary artery disease, heart failure, heart valve disorders, hypertension, and lipid disorders, performing both diagnostic and therapeutic invasive procedures. He is also actively involved in European and international cardiology initiatives, contributing directly to innovations in cardiovascular diagnostics, treatment, and digital health.
Today, we sit down with Dr. Pranevičius to discuss the revolutionary impact of GLP-1 receptor agonists on cardiovascular care, the future of digital health tracking, and the reality behind the “biohacking” buzz.
Shifting the Narrative: From Weight Loss to Vascular Shield
Most people view GLP-1 medications solely through the lens of weight loss, especially with the recent media buzz around Ozempic. Based on clinical research, how do these medications shift our understanding of heart health?
The topic of GLP-1s is highly sensitive for both physicians and patients, largely because it initially gained fame for obesity and rapid weight loss. However, from a medical standpoint, what we are actually dealing with is a hormone naturally released by the gut – and its role is far broader than just signaling fullness.
GLP-1 receptors are present in blood vessel walls, immune cells, and cardiac tissue. When activated pharmacologically, you aren’t just suppressing appetite; you are simultaneously influencing vascular inflammation, plaque behavior, and endothelial function.
The real turning point for me was the SELECT trial. It evaluated individuals with obesity and established heart disease, crucially without diabetes, and still demonstrated a roughly 20% relative reduction in major adverse cardiovascular events. This proves that the cardiac benefit is not merely a side effect of improved blood sugar. We now have a drug class that targets multiple cardiovascular pathways at once, rather than just adjusting a single number on a lab panel. That is the true game-changer.
The Holy Grail of Cardiology: Cellular Repair and “Vascular Regeneration”
You have highlighted the emerging concept of “vascular regeneration” – the idea that these drugs might help the body actively repair its own blood vessels. How close are we to proving this?
This is easily one of the most intellectually fascinating and humbling areas of current research. Hypotheses published in the American Journal of Physiology suggest that GLP-1 receptor agonists might support actual vascular repair, creating a more favorable micro-environment for vessel health rather than just slowing down damage.
To be honest, we are in the early stages. While the mechanistic evidence is biologically plausible, we do not yet have the clinical trial infrastructure to isolate regeneration as a distinct outcome. What we do know is that the cardiovascular benefits observed in clinical trials cannot be fully explained by any single known mechanism. Vascular regeneration is a compelling explanation for that gap. It may take another decade of targeted studies to know for certain, but the fact that major cardiovascular journals are publishing on this shows the hypothesis has real merit.
With the rising interest in “biohacking” and longevity, do you view these GLP-1 findings as a tool to help humans remain “metabolically young” as they age?
That framing resonates with me, but it must be grounded in science. The observed effects of GLP-1 activation on vascular inflammation, endothelial function, and potential tissue repair map closely onto the exact biological processes that dictate how “metabolically aged” our cardiovascular system becomes over time. While it doesn’t reverse aging, it appears to favorably influence the rate at which these systems deteriorate.
The SELECT trial was striking because these benefits appeared in individuals without diabetes, indicating the drug acts on a core mechanism of obesity-related vascular aging rather than just glucose control. If the vascular regeneration hypothesis holds up, we are looking at a tool that does more than just correct a disease state – it may actively preserve cardiovascular healthspan.
However, we must treat this with appropriate medical caution – it still requires strict clinical indications. Ultimately, healthy nutrition, physical activity, sleep, and genetics remain the foundational core of longevity. GLP-1 science is an incredibly powerful addition to the toolkit, but it works best alongside the fundamentals.
A Tool, Not a Universal Cure
Since these drugs show benefits even in people without diabetes, are we entering an era where everyone should proactively use this science to “shield” their heart?
This requires a nuanced answer. The evidence strongly supports proactive cardiovascular protection for individuals carrying substantial risk – specifically those living with obesity and established arterial disease. For this group, the clinical case is compelling.
However, I would pump the brakes on the idea of this becoming a universal intervention for anyone looking to “optimize” their health. Medicine is not there yet, and there are real safety considerations – such as gallbladder and biliary disease, which research in JAMA Internal Medicine has clearly flagged.
We are entering an era where advanced cardiovascular protection can be extended to previously underserved populations whose risks stem from obesity-related biology rather than diabetes alone. That is incredibly exciting. But claiming that “everyone should take this” goes beyond what the current evidence supports.
Breaking the Silos: The Next Generation of Connected Health Tech
You often mention that the heart and kidneys work together as a team. How should understanding this “teamwork” shape the future of health apps and technology?
Clinicians have intuitively known about the cardiorenal connection for a long time, but hard clinical data has only recently emerged. The FLOW trial was pivotal here: it tracked patients with type 2 diabetes and chronic kidney disease, revealing that semaglutide simultaneously improved kidney outcomes and reduced cardiovascular mortality. These two systems move together, not independently.
For health technology developers, integrating this biological reality should be mandatory. If you design a wellness app that tracks only one isolated organ system, like blood pressure or eGFR alone, you miss the bigger picture. Today’s patients are highly informed, often using AI tools to research their conditions, and digital health platforms need to keep pace with them.
Cardiovascular and renal signals must be analyzed together. A meaningful digital health platform should surface patterns across these interconnected systems instead of separating them into isolated dashboards. The next generation of risk-prediction tools must reflect this integrated biology.
Kilo focuses heavily on health and wellness solutions. Do you foresee a future where we can use data and health apps to analyze these interconnected systems and predict who will benefit most?
The healthcare industry isn’t fully there yet, but the trajectory is highly promising and we’re getting there step by step. Current evidence helps us identify broad target categories – such as high cardiovascular risk, obesity, and diabetes status – but individual responses within those groups still vary due to biology and tolerability.
This is exactly why platforms like Kilo are so exciting. Gathering longitudinal individual data – weight trajectories, inflammatory markers, physical function, and patient-reported symptoms – creates the dense datasets required to drive more tailored prediction.
The future of advanced medical care is arriving rapidly, and specialized centers are already being built for this, including an upcoming center, Bio City III, in Vilnius! The biology is too complex for a simple, static risk score, but an AI model trained on continuous, real-world health data can unlock highly accurate clinical predictions. Transforming cardiovascular medicine through digital health infrastructure is a realistic near-term goal.
